Clovis Oncology
Data Breaches, Cyber Attacks and Security Report

https://clovisoncology.com  ᛫ 
Last updated November 12, 2019

About Clovis Oncology

Company Overview

Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

Valuation

Employees

CEO

Location

Data Breaches and Security News

Clovis Oncology Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Clovis Oncology is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Clovis Oncology

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Clovis Oncology's security performance with other companies